Why the study?
Do metabolic modulators provide benefits in the management of patients with coronary artery disease?
Do metabolic modulators provide benefits in the management of patients with coronary artery disease?
Metabolic modulators represent a potential class of agents for the management of ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Metabolic modulators in ischemic heart disease require prospective trials; current evidence leaves open any role in coronary artery disease management.
The number of patients with coronary artery disease and its risk factors is increasing in Western nations. New treatments for these patients may soon include a class of agents known as the metabolic modulators. This group of agents consists of the partial fatty acid oxidation inhibitors trimetazidine and ranolazine, as well as dichloroacetate, which promotes carbohydrate utilization. Metabolic modulators also include the nutriceuticals L-carnitine and D-ribose. The available evidence regarding the benefits of each of these five agents is reviewed.
No takes yet. Share an insight, caveat, or question.
Pauly et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: